ArticleBreast cancer research and treatment2022

Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study.

Elaine M Walsh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.